hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06368687, orgStudyIdInfo id: 2023-06112-01, briefTitle: TRANPAS - TReating Anorexia Nervosa Plus Autism Spectrum, acronym: TRANPAS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Göteborg University, class: OTHER, descriptionModule briefSummary: In a pilot study, we will validate a so-called autism care location in an inpatient ward. The care location will be adapted for patients with anorexia nervosa (AN) and concurrent autism (AN+autism). In order to investigate the effect of a tailored care location for patients with AN + autism, the evaluation will include weight development and changes in nutritional intake, eating disorder and anxiety symptoms. The overall aim is to improve treatment for this specific AN subgroup, that otherwise has a worse prognosis regarding AN recovery., conditionsModule conditions: Anorexia Nervosa, conditions: Autism Spectrum Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Pilot study. Ten consecutive patients with anorexia nervosa (AN) plus autism will be admitted to the autism care location at an inpatient ward for eating disorders. The planned period of care for each patient is 12 weeks. The patient will be assessed (including weight, height, self-report questionnaires and interviews) before admission, at discharge and 6 months later., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Anorexia nervosa plus autism, outcomesModule primaryOutcomes measure: BMI change between baseline and discharge 12 weeks later, secondaryOutcomes measure: Change of level of anxiety between baseline and discharge 12 weeks later, secondaryOutcomes measure: Change of Quality of life between baseline and discharge 12 weeks later, eligibilityModule sex: ALL, minimumAge: 25 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06368661, orgStudyIdInfo id: 23.79 Colo-MAR 1, briefTitle: Dietary Factors Associated to Colorectal Premalignant Lesions (COLOMAR-1), statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Fundación Vithas, class: OTHER, collaborators name: CEU San Pablo University, descriptionModule briefSummary: This study aims to find a correlation between fish protein intake and other dietary habits and colorectal premalignant lesions in healthy volunteers. It also aims to describe gut microbial profiles for each dietary pattern, in order to elucidate the role of fish intake in cancer prevention., conditionsModule conditions: Nutrition Related Neoplasm/Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 30, type: ESTIMATED, outcomesModule primaryOutcomes measure: Dietary habits registry from participants: the dietary intake, primaryOutcomes measure: Biomarkers in colon mucosa, precancerous lesions and colorectal cancer, primaryOutcomes measure: Gut microbiota profile, eligibilityModule sex: ALL, minimumAge: 45 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ciro Cabezas Checchi, status: RECRUITING, city: Vigo, state: Pontevedra, zip: 36206, country: Spain, contacts name: Ciro Cabezas Checchi, MD, role: CONTACT, phone: +34 986 82 11 00, email: CabezasCC@vithas.es, geoPoint lat: 42.23282, lon: -8.72264, hasResults: False
protocolSection identificationModule nctId: NCT06368622, orgStudyIdInfo id: CDM10001814, briefTitle: Evolve China PMCF Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2027-11, completionDateStruct date: 2031-08, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Stryker Neurovascular, class: INDUSTRY, collaborators name: Stryker (Beijing) Healthcare Products Co., Ltd, descriptionModule briefSummary: A prospective, multi-center, single-arm, open-label, observational post-market real-world registry. The expected duration of the study is 8 years (including up to 5-years' follow-up).Each subject will be followed in accordance with the standard of care (SOC) at each participating hospital., conditionsModule conditions: Intracranial Aneurysm, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Surpass Evolve Flow Diverter System, outcomesModule primaryOutcomes measure: Neurological death or disabling stroke, primaryOutcomes measure: 100% occlusion without significant parent artery stenosis, secondaryOutcomes measure: Procedure- and device-related serious adverse events, secondaryOutcomes measure: Key neurological events, secondaryOutcomes measure: Procedural success, secondaryOutcomes measure: Device success, secondaryOutcomes measure: Re-sheathing success, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xuanwu Hospital Capital Medical University, city: Beijing, state: Beijing, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06368609, orgStudyIdInfo id: 2024-09, briefTitle: Preliminary Evaluation of Two Rapid Diagnostic Test Prototypes for Strongyloides Stercoralis Infection, acronym: PROTOSS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: IRCCS Sacro Cuore Don Calabria di Negrar, class: OTHER, descriptionModule briefSummary: Single center, no profit experimental study on sera available in the Tropica Biobank., conditionsModule conditions: Strongyloides Stercoralis Infection, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: IgG RDT, interventions name: IgG4 RDT, outcomesModule primaryOutcomes measure: RDTs IgG results: positive or negative, primaryOutcomes measure: RDTs IgG4 results: positive or negative, secondaryOutcomes measure: Agreement between readers, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IRCCS Sacro Cuore Don Calabria hospital, city: Negrar, state: Verona, zip: 37024, country: Italy, contacts name: Dora Buonfrate, role: CONTACT, email: dora.buonfrate@sacrocuore.it, contacts name: Dora Buonfrate, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.52918, lon: 10.93899, hasResults: False
protocolSection identificationModule nctId: NCT06368596, orgStudyIdInfo id: 2024-04, briefTitle: ENDS (ENDometriosis & FuSobacterium) Unveiling the Contribution of Fusobacterium Infection to the Development of Endometriosis, acronym: ENDS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-10, completionDateStruct date: 2025-10, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: IRCCS Sacro Cuore Don Calabria di Negrar, class: OTHER, descriptionModule briefSummary: This will be a clinical interventional longitudinal study, without pharmacological intervention/device evaluation.A control group would however be recruited for secondary objective 1 and 2.The study is classified as interventional, as Fusobacterium detection is not part of the routine management of these patients; from the patients' point of view, participation in the study will involve the execution of additional vaginal and cervical swabs as additional procedure, while the endometrial biopsy will not represent an additional examination, as the study will include only patients for whom this examination is expected as per normal clinical practice., conditionsModule conditions: Endometriosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 845, type: ESTIMATED, armsInterventionsModule interventions name: Fusobacterium detection, outcomesModule primaryOutcomes measure: Fusobacterium sp presence (Y/N) in endometrial biopsy in women with endometriosis, secondaryOutcomes measure: Fusobacterium presence (Y/N) in endometrial biopsy in women without endometriosis, secondaryOutcomes measure: Fusobacterium presence (Y/N) in vaginal and cervical swab in all women enrolled, secondaryOutcomes measure: Fusobacterium presence (Y/N) in endometrial biopsy in women with and without PID complicating endometriosis ., secondaryOutcomes measure: Fusobacterium presence (Y/N) in biopsies of endometrial tissue involving different sites (superficial lesions, deep endometriosis, ovarian endometrioma), if present, secondaryOutcomes measure: Fusobacterium presence (Y/N) in endometrial biopsy in women with and without infertility associated to endometriosis, secondaryOutcomes measure: Fusobacterium presence (Y/N) in endometrial biopsy in women with and without hysteroscopic signs of chronic endometritis in patients with and without endometriosis, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IRCCS Sacro Cuore Don Calabria di Negrar, city: Negrar, state: Verona, country: Italy, contacts name: Marcello Ceccaroni, Doctor, role: CONTACT, email: marcello.ceccaroni@sacrocuore.it, contacts role: CONTACT, phone: 0456013111, contacts name: Marcello Ceccaroni, role: PRINCIPAL_INVESTIGATOR, contacts name: Dora Buonfrate, role: SUB_INVESTIGATOR, geoPoint lat: 45.52918, lon: 10.93899, hasResults: False
protocolSection identificationModule nctId: NCT06368544, orgStudyIdInfo id: M2023816, briefTitle: Effect of Early Gait Training on Knee Cartilage Degeneration After Anterior Cruciate Ligament Reconstruction, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-07, primaryCompletionDateStruct date: 2030-02-07, completionDateStruct date: 2030-02-07, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Peking University Third Hospital, class: OTHER, descriptionModule briefSummary: A randomized controlled clinical study was conducted to elucidate the relationship between the lower extremity biomechanics of patients undergoing early gait training after ACLR surgery.The relationship between the biochemical characteristics of cartilage and the biomechanical risk index were proposed to providing exercise guidance and training for middle-aged people and it is suggested that it can prevent and reduce the risk of cartilage degeneration early after operation., conditionsModule conditions: Anterior Cruciate Ligament Injuries, conditions: Cartilage Degeneration, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: lower-body positive-pressure, outcomesModule primaryOutcomes measure: Gait biomechanical data, primaryOutcomes measure: Gait biomechanical data, primaryOutcomes measure: Gait biomechanical data, primaryOutcomes measure: Gait biomechanical data, primaryOutcomes measure: Gait biomechanical data, primaryOutcomes measure: Biochemical characteristics of knee cartilage, primaryOutcomes measure: Biochemical characteristics of knee cartilage, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Peking University Third Hospital, status: RECRUITING, city: Beijing, country: China, contacts name: ren shuang, role: CONTACT, phone: xixishuang123@126.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06368518, orgStudyIdInfo id: ID01/2024/MZHCM-Reg/NV, briefTitle: Austrian HCM Registry, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-08, primaryCompletionDateStruct date: 2034-03, completionDateStruct date: 2034-03, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Medical University of Graz, class: OTHER, descriptionModule briefSummary: The Austrian Hypertrophic Cardiomyopathy (HCM) Registry is a prospective, multicenter registry enrolling patients at multiple outpatient clinics across Austria including academic and non-academic centers. Patients will undergo a structured examination process including assessment for symptoms of HCM, past medical history, concomitant medication, family history and the presence of HCM-specific red flags. Furthermore, clinical data derived from electrocardiogram, echocardiography, laboratory analysis, and genetic testing will be collected focusing on a lean variable dictionary and, in addition, specific hypothesis-driven research parameters. All data are entered into an electronic case report form (eCRF) (Phoenix Clinical Trial Management System). In order to perform multicenter analyses, data can be extracted from the eCRF after approval by the steering committee., conditionsModule conditions: Hypertrophic Cardiomyopathy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, outcomesModule primaryOutcomes measure: All cause mortality, primaryOutcomes measure: Cardiovascular events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medical University of Graz, status: RECRUITING, city: Graz, state: Styria, zip: 8036, country: Austria, contacts name: Nicolas Verheyen, MD, PHD, role: CONTACT, phone: 004331638530173, email: nicolas.verheyen@medunigraz.at, contacts name: Viktoria Santner, MD, role: CONTACT, email: viktoria.santner@medunigraz.at, contacts name: Nicolas Verheyen, MD, PHD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 47.06667, lon: 15.45, hasResults: False
protocolSection identificationModule nctId: NCT06368505, orgStudyIdInfo id: R.24.02.2506.R1, briefTitle: Platelet-Rich Plasma Injection Versus Hydrodissection in the Treatment of Carpal Tunnel Syndrome, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-16, primaryCompletionDateStruct date: 2024-06-16, completionDateStruct date: 2024-07-16, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Osama Ahmed Elshafei, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare the efficacy of Ultrasound-Guided Platelet-Rich Plasma Injection versus Hydrodissection (using 2ml saline, 2ml dexamethasone and 1ml lidocaine) in the Treatment of Carpal Tunnel Syndrome. The main questions it aims to answer are:* Which modality is more effective in reducing symptoms and improving function in patients with Carpal tunnel syndrome* Asses safety profile of both methodsParticipants will:* Randomized to one of the two arms* Visit the clinic 1 and 3 months after intervention* Assessed for efficacy and safety of the intervention, conditionsModule conditions: Carpal Tunnel Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: ultrasound guided PRP injection, interventions name: ultrasound guided hydrodissection, outcomesModule primaryOutcomes measure: Boston Carpal Tunnel Syndrome Questionnaire (BCTQ), primaryOutcomes measure: The visual analog scale (VAS), secondaryOutcomes measure: The cross-sectional area (CSA) of the Median nerve, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mansoura University, status: RECRUITING, city: Mansoura, zip: 35511, country: Egypt, contacts name: osama elshafei, MD PHD, role: CONTACT, email: osama_elshafei@mans.edu.eg, contacts name: Dena El-Ghzzawy, role: CONTACT, email: Profdr_os@yahoo.com, contacts name: Dena El-Ghzzawy, MD, role: SUB_INVESTIGATOR, contacts name: OSAMA ELSHAFEI, MD PHD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.03637, lon: 31.38069, hasResults: False
protocolSection identificationModule nctId: NCT06368479, orgStudyIdInfo id: CLS-016B, briefTitle: A Prospective Cross-Sectional Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-07-01, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: bioLytical Laboratories, class: INDUSTRY, descriptionModule briefSummary: A prospective cross-sectional study in which surgically non-invasive sample-taking is done only for the purpose of testing the samples on iStatis HBsAg Test at the point of care., conditionsModule conditions: Hepatitis B, conditions: Hepatitis B Infection, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SCREENING, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 4400, type: ESTIMATED, armsInterventionsModule interventions name: iStatis HBsAg Test, outcomesModule primaryOutcomes measure: iStatis Performance, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Epicentre Health Research, status: RECRUITING, city: Hillcrest, state: Kwazulu Natal, zip: 3650, country: South Africa, contacts name: Cherie Cawood, role: CONTACT, phone: +27828202955, email: cheriec@epicentre.org.za, hasResults: False
protocolSection identificationModule nctId: NCT06368466, orgStudyIdInfo id: CLS-016A, briefTitle: A Prospective Cross-Sectional Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2024-08-30, completionDateStruct date: 2024-09-01, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: bioLytical Laboratories, class: INDUSTRY, collaborators name: St Vincent's Hospital Melbourne, descriptionModule briefSummary: A prospective cross-sectional study in which surgically non-invasive sample-taking is done only for the purpose of the study. Capillary (fingerstick) whole blood and EDTA venipuncture whole blood are collected by a healthcare professional. The collected samples of capillary and EDTA whole blood are tested on iStatis and EDTA whole blood sample will be processed to obtain serum and plasma samples to be tested on the iStatis. An aliquot of the collected serum sample will be shipped to the central laboratory for confirmatory testing. The results from iStatis HBsAg Test results will not be used for patient management decisions., conditionsModule conditions: Hepatitis B, conditions: Hepatitis B Infection, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 350, type: ESTIMATED, armsInterventionsModule interventions name: iStatis HBsAg Test, outcomesModule primaryOutcomes measure: Performance, primaryOutcomes measure: Sensitivity and Specificity, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: St. Vincent's Hospital, Melbourne, city: Melbourne, state: Fitzroy Victoria, zip: 3065, country: Australia, contacts name: Alex Thompson, role: CONTACT, geoPoint lat: -37.814, lon: 144.96332, hasResults: False
protocolSection identificationModule nctId: NCT06368453, orgStudyIdInfo id: CLS-003, briefTitle: A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2025-05-01, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: bioLytical Laboratories, class: INDUSTRY, descriptionModule briefSummary: The objective of this study is to evaluate the performance, usability, and result interpretation of the INSTI® HIV Self-Test (referred to INSTI® HIV ST) in the intended use population across the United States (US). The INSTI® HIV Self-Test is a single use in vitro test that is used as a self-test for the detection of antibodies to HIV-1 and HIV-2 in human fingerstick blood. This study is designed to evaluate INSTI® HIV ST performance in the hands of non-professionals and untrained lay users who are inexperienced in HIV blood-based self-testing.The study aims to:To evaluate the clinical performance (i.e., diagnostic sensitivity and specificity) of the INSTI® HIV Self-Test in a lay user population.To assess the user's comprehension of the INSTI® HIV ST results (e.g., interpreting positive, negative, and invalid results).To evaluate the usability of the INSTI® HIV ST and understand users' experience in performing the test., conditionsModule conditions: Human Immunodeficiency Virus I Infection, conditions: Human Immunodeficiency Virus II Infection, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: SINGLE, whoMasked: CARE_PROVIDER, enrollmentInfo count: 1700, type: ESTIMATED, armsInterventionsModule interventions name: INSTI® HIV Self-Test, outcomesModule primaryOutcomes measure: Clinical sensitivity and specificity of the INSTI® HIV Self-Test, secondaryOutcomes measure: The INSTI® HIV Self-Test usability and result interpretation, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False